JOURNAL REPRINTS WITH "REFERENCE TO" UNAPPROVED USES WOULD BE ALLOWED UNDER FDA PROMOTION REFORM; TEXTBOOK DISSEMINATION OKAY IF OFF-LABEL USE NOT "HIGHLIGHTED"
FDA will allow companies to disseminate journal reprints of studies used to support an approved indication that include incidental references to off-label uses, the agency said Nov. 21. "FDA has determined that certain peer-reviewed journal reports upon which FDA relied for approval of a product may be distributed even if they contain information (e.g., reference to unapproved uses) that is inconsistent with the FDA-approved labeling for the product," an agency "Talk Paper" on the reforms states.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth